文献速递主动脉疾病

Zenith TX1与TX2装置胸主动脉腔内修复的持久疗效

Durable outcomes of thoracic endovascular aortic repair with Zenith TX1 and TX2 devices.
PubMed 文献 · J Vasc Surg · 2017-02-16

本研究前瞻性纳入200例高危降主动脉病变患者,接受Zenith TX1/TX2胸主动脉腔内修复,平均随访4.8±3.3年。结果显示手术死亡率6.5%,9年动脉瘤相关生存率91.7%,但内漏发生率达28%,需长期影像随访。

要点

  • TEVAR术后9年动脉瘤相关生存率91.7%,疗效持久
  • 内漏发生率28%,需长期影像监测

核心结论

  • TEVAR持久且与高长期动脉瘤相关生存率相关,长期影像随访仍至关重要。

研究设计与样本

  • 前瞻性、医生发起的IDE试验,2001-2011年纳入200例高危降主动脉病变患者。

主要发现

  • 手术死亡率6.5%,30天、1、5、9年生存率分别为94.0%、85.8%、55.6%、31.4%。
  • 动脉瘤相关免于死亡在30天、1、5、9年分别为94.0%、92.4%、91.7%、91.7%。
  • 30天、1、5、9年免于再干预分别为87.9%、82.9%、75.5%、64.0%。

临床怎么用

  • 高危降主动脉病变患者可考虑TEVAR,但需坚持长期影像随访以发现内漏或装置耐久性问题。
  • 多数内漏和再干预可通过腔内技术监测或处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-term data regarding the safety and durability of thoracic endovascular aortic repair (TEVAR) are limited. The study objective was to evaluate the long-term outcomes of TEVAR in high-risk patients with descending thoracic aortic pathology. METHODS: High-risk patients were treated with thoracic endografts (2001-2011) under a prospective, physician-sponsored, investigational device exemption trial. Three-dimensional reconstructions and measurements were performed on computed tomography scans acquired before discharge, at 1, 6, and 12 months, and then yearly thereafter. RESULTS: The study included 200 patients, of whom 171 were treated for thoracic aneurysm, 28 for chronic dissection, and 1 for aortobronchial fistula. Patients were monitored for an average of 4.8 ± 3.3 years, and 93 (46.5%) were monitored for >5 years. Operative mortality was 6.5%. Survival at 30 days and at 1, 5, and 9 years was 94.0%, 85.8%, 55.6%, and 31.4%, and freedom from aneurysm-related death was 94.0%, 92.4%, 91.7%, 91.7%, respectively. Sixty-one endoleaks occurred in 54 patients (28%). Sixty-seven reinterventions were performed in 50 patients. Overall freedom from reintervention at 30 days, 1, 5, and 9 years was 87.9%, 82.9%, 75.5%, and 64.0%, respectively. Forty-seven reinterventions (70%) were thoracic aneurysm-related, 35 (74%) of which were endovascular procedures. Thirty of these were to correct endoleaks at a median of 1.4 years (interquartile range, 0.2-5.0 years). CONCLUSIONS: TEVAR is durable and associated with high long-term aneurysm-related survival. Long-term imaging follow-up remains critical to identify endoleaks or rare device durability issues, most of which can be monitored or managed with endovascular therapies.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Beach JM, Kuramochi Y, Brier C, et al. Durable outcomes of thoracic endovascular aortic repair with Zenith TX1 and TX2 devices. J Vasc Surg. 2017. PMID: 28216363. doi:10.1016/j.jvs.2016.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。